Raghava K. Kashyap

St Andrews Place
Melbourne, VIC 3002, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.

Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 16, 2026

Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.

Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.

Journal: The Lancet. Oncology

Published: August 07, 2025

Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.

Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 07, 2025

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.

Journal: The Lancet. Oncology

Published: April 17, 2025

Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.

Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 06, 2025

Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.

Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 07, 2025

Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience.

Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 10, 2025

Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: A scoping review.

Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: A scoping review.

Journal: Journal of neuroendocrinology

Published: February 10, 2024

Clinical Positron Emission Tomography/Computed Tomography: Quarter-Century Transformation of Prostate Cancer Molecular Imaging.

Clinical Positron Emission Tomography/Computed Tomography: Quarter-Century Transformation of Prostate Cancer Molecular Imaging.

Journal: PET clinics

Published: January 10, 2024

'Case of the Month' from Peter MacCallum Cancer Centre, Melbourne, Australia: insidious presentation of iatrogenic renal pelvis injury following ureteric cannulation with 5-F catheter diagnosed on unconventional mercaptoacetyltriglycine and single-photon emission computed tomography imaging.

'Case of the Month' from Peter MacCallum Cancer Centre, Melbourne, Australia: insidious presentation of iatrogenic renal pelvis injury following ureteric cannulation with 5-F catheter diagnosed on unconventional mercaptoacetyltriglycine and single-photon emission computed tomography imaging.

Journal: BJU international

Published: December 27, 2023

Correlation of current myocardial perfusion imaging and previous coronary angiography to avert the need for repeat intervention - A case report.

Correlation of current myocardial perfusion imaging and previous coronary angiography to avert the need for repeat intervention - A case report.

Journal: Journal of medical imaging and radiation sciences

Published: March 18, 2023

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review.

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review.

Journal: Therapeutic advances in medical oncology

Published: March 17, 2023

Showing 1-12 of 66

Last Updated: 09/26/2026